News | July 07, 2023
Alkem forays into ophthalmology with launch of eye care products
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
PEEK brings a new quality to dental care for patients
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The company is already marketing the 4 mg and 10 mg strengths
Subscribe To Our Newsletter & Stay Updated
